Analysts Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $20.00

Shares of Altimmune, Inc. (NASDAQ:ALT) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $20.00.

Several research firms have commented on ALT. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday, November 14th. UBS Group initiated coverage on shares of Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company.

Altimmune Stock Down 6.7 %

ALT opened at $8.40 on Friday. The firm has a 50-day simple moving average of $7.81 and a two-hundred day simple moving average of $7.08. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84. The company has a market capitalization of $597.45 million, a PE ratio of -5.42 and a beta of 0.15.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million during the quarter. During the same period last year, the company earned ($0.39) EPS. As a group, sell-side analysts expect that Altimmune will post -1.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Bellevue Group AG lifted its stake in Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after purchasing an additional 263,660 shares during the last quarter. Virtu Financial LLC bought a new stake in Altimmune in the third quarter worth about $674,000. SG Americas Securities LLC lifted its stake in Altimmune by 542.8% in the second quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after purchasing an additional 214,968 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after purchasing an additional 335,444 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in Altimmune in the second quarter worth about $860,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.